Welcome to our dedicated page for Nuvation Bio news (Ticker: NUVB), a resource for investors and traders seeking the latest updates and insights on Nuvation Bio stock.
Nuvation Bio Inc (NUVB) is a clinical-stage biopharmaceutical company pioneering novel therapies for challenging cancers through innovative platforms like BD2-selective BET inhibitors and Drug-Drug Conjugate technology. This page serves as the definitive source for tracking the company’s progress in oncology research and corporate developments.
Investors and industry observers will find timely updates on clinical trial milestones, regulatory filings, and strategic partnerships. All press releases and news articles are organized to provide clear insights into Nuvation Bio’s work targeting epigenetic regulators and advanced drug delivery systems.
Key content includes updates on lead candidate NUV-868, financial results, and scientific presentations. The page is regularly updated to reflect the most current information about the company’s efforts to develop precision oncology treatments.
Bookmark this page to stay informed about Nuvation Bio’s advancements in creating therapies for tumors resistant to conventional treatments. Check back frequently for verified updates directly from corporate communications and trusted industry sources.
Nuvation Bio has published data from its Phase 2 TRUST-I study of taletrectinib, a ROS1 inhibitor, in the Journal of Clinical Oncology and presented at the 2024 ASCO Annual Meeting.
This study involved 173 patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) in China. Results showed that tumors shrank in 91% of ROS1 TKI-naïve and 52% of ROS1 TKI-pretreated patients.
Long-term follow-up indicated 71% of TKI-naïve patients remained progression-free at two years. The study highlighted taletrectinib's effectiveness in patients with brain metastases and resistance mutations.
Safety profile was consistent with previous reports, showing low incidence of neurologic treatment-emergent adverse events.
Nuvation Bio, a late clinical-stage biopharmaceutical company focused on oncology, announced that its CEO, David Hung, M.D., will present at the Jefferies Global Healthcare Conference. The event will take place on June 5, 2024, at 1:30 p.m. ET. A live webcast of the presentation will be available on the Nuvation Bio website, with an archived recording accessible for 90 days.
Nuvation Bio (NYSE: NUVB) reported its Q1 2024 financial results, highlighted by the acquisition of AnHeart Therapeutics, transforming it into a late-stage oncology company. Updated data from the Phase 2 TRUST-I study of taletrectinib, a ROS1 inhibitor, will be presented at the 2024 ASCO Annual Meeting. The company also initiated a Phase 1/2 study of NUV-1511, a drug-drug conjugate for advanced solid tumors.
As of March 31, 2024, Nuvation Bio had $597.0 million in cash and securities. Q1 research and development expenses were $12.8 million, down from $18.8 million in Q1 2023, while general and administrative costs were $7.3 million, slightly down from $7.7 million. The net loss was $14.8 million, or $(0.07) per share, compared to $21.7 million, or $(0.10) per share, in Q1 2023.
FAQ
What is the current stock price of Nuvation Bio (NUVB)?
What is the market cap of Nuvation Bio (NUVB)?
